Drug products: Clarityn, Clarityn®, Loratadin 2care4, Loratadin ABECE, Loratadin Actavis, Loratadin Apofri, Loratadin BMM Pharma, Loratadin HEXAL, Loratadin Mylan, Loratadin Orifarm, Loratadin ratiopharm, Loratadin Sandoz, Loratadin STADA®, Versal®
ATC code: R06AX13
Controlled studies on sex differences in efficacy and safety of loratadine are lacking.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics of loratadine has been found.
No studies with a clinically relevant sex analysis regarding the effects of loratadine has been found.
An observational study based on data from General Practice Research Database in the UK (in total 197 425 persons) investigated the incidence of ventricular arrhythmias associated with use of non-sedating antihistamines (acrivastine, astemizole, cetirizine, loratadine and terfenadine). Ventricular arrhythmias were four times more common in those using non-sedating antihistamines compared to those with no use. The relative risk in women compared to men was 1.1 (95% CI 0.4-2.9) .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2018-12-14
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson